Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Veracyte, Inc. - Common Stock (NQ:VCYT)

43.34 +1.87 (+4.50%)
Streaming Delayed Price Updated: 1:10 PM EDT, Aug 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Veracyte, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
VERACYTE INC (NASDAQ:VCYT) stands out as a growth opportunity that won't break the bank. ↗
Discover VERACYTE INC, an undervalued growth gem. NASDAQ:VCYT is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing... 
Via Chartmill
News headline image
A Glimpse Into The Expert Outlook On Veracyte Through 5 Analysts ↗
 
Via Benzinga
News headline image
Diagnostic Company Veracyte Weighs Sale For French Subsidiary, Analyst Says 'Walking Away' Is A Long-Term Positive ↗
Veracyte topped Q4 earnings and revenue estimates as testing volume grew. The company is evaluating options for its French unit. 
Via Benzinga
News headline image
Veracyte Announces Fourth Quarter and Full Year 2024 Financial Results
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Participate in Upcoming Investor Conferences
From Veracyte, Inc.
Via Business Wire
News headline image
Why VERACYTE INC (NASDAQ:VCYT) qualifies as a high growth stock. ↗
A fundamental and technical analysis of (NASDAQ:VCYT): Is VERACYTE INC (NASDAQ:VCYT) suited for high growth investing? 
Via Chartmill
News headline image
Demystifying Veracyte: Insights From 7 Analyst Reviews ↗
 
Via Benzinga
News headline image
Exploring NASDAQ:VCYT's high growth characteristics. ↗
Why VERACYTE INC (NASDAQ:VCYT) qualifies as a high growth stock. 
Via Chartmill
News headline image
Earnings Scheduled For February 24, 2025 ↗
 
Via Benzinga
News headline image
Should you consider VERACYTE INC (NASDAQ:VCYT) for high growth investing? ↗
Unlocking the high Growth Potential of VERACYTE INC (NASDAQ:VCYT). 
Via Chartmill
News headline image
Navigating 9 Analyst Ratings For Veracyte ↗
 
Via Benzinga
News headline image
Is NASDAQ:VCYT a Fit for high Growth Investing Strategies? ↗
Should you consider VERACYTE INC (NASDAQ:VCYT) for high growth investing? 
Via Chartmill
News headline image
Breaking Down Veracyte: 4 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests’ Leadership in Urologic Cancers to Be Presented at the 2025 ASCO GU Symposium
From Veracyte
Via Business Wire
News headline image
New Study Shows Veracyte’s Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder Cancer
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Release Fourth Quarter and Full-Year 2024 Financial Results on February 24, 2025
From Veracyte, Inc.
Via Business Wire
News headline image
Cathie Wood's Ark Invest Trims Palantir Again As Peter Thiel Co-Founded Firm's Stock Tumbles Nearly 15% In 2025 ↗
Cathie Wood-led Ark Invest sold 140,518 shares of Palantir and bought shares of Tempus AI Inc. The total value of the trades is about $9.1 million. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Veracyte’s Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer Guidelines
From Veracyte, Inc.
Via Business Wire
News headline image
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared? ↗
Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Smaller Cap Biotechs Are In Season: How Are We Doing? ↗
SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range. 
Via Talk Markets
News headline image
Veracyte Announces Third Quarter 2024 Financial Results
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Participate in Upcoming Investor Conferences
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Release Third Quarter 2024 Financial Results on November 6, 2024
From Veracyte, Inc.
Via Business Wire
News headline image
New Data Presented at ASTRO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Aggressive Prostate Cancer in African American Men
From Veracyte, Inc.
Via Business Wire
News headline image
Tempus AI Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating ↗
A Relative Strength Rating upgrade for Tempus AI shows improving technical performance. 
Via Investor's Business Daily
Topics Artificial Intelligence
News headline image
New Data Presented at ESMO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Named a Greater Bay Area Top Workplace by the San Francisco Chronicle
From Veracyte, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.